Search results for "From ACP Internist"
ADA, EASD update guidance on managing hyperglycemia
An updated consensus statement from the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) addressed social drivers of health, lifestyle modifications, and new drug classes for type 2 diabetes.
https://diabetes.acponline.org/archives/2022/10/14/7.htm
14 Oct 2022
Some newer diabetes drugs may help decrease risk of COPD exacerbation
A cohort study in the United Kingdom found that chronic obstructive pulmonary disease (COPD) exacerbations were less common in patients with type 2 diabetes and COPD taking glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors versus sulfonylureas.
https://diabetes.acponline.org/archives/2022/11/11/6.htm
11 Nov 2022
GLP-1 receptor agonists associated with thyroid cancer
Patients taking a glucagon-like peptide-1 (GLP-1) receptor agonist had about one and a half times the risk of developing thyroid cancer compared to similar controls, according to an observational French study.
https://diabetes.acponline.org/archives/2022/12/09/6.htm
9 Dec 2022
Some newer diabetes drugs may help decrease risk of COPD exacerbation
A cohort study in the United Kingdom found that chronic obstructive pulmonary disease (COPD) exacerbations were less common in patients with type 2 diabetes and COPD taking glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors versus sulfonylureas.
https://diabetes.acponline.org/archives/2022/12/09/7.htm
9 Dec 2022
ADA updates diabetes standards of care for 2023
The American Diabetes Association (ADA) has changed its recommendations on hypertension cutoffs, use of statins, and treatment of patients with diabetes and chronic kidney disease, among other topics.
https://diabetes.acponline.org/archives/2023/01/13/5.htm
13 Jan 2023
Overweight, obesity poorly managed in type 1 diabetes
While U.S. adults with type 1 diabetes have rates of overweight and obesity virtually identical to those in the general adult population, only about 50% received lifestyle recommendations for weight management from clinicians or tried lifestyle modifications.
https://diabetes.acponline.org/archives/2023/03/10/9.htm
10 Mar 2023
Getting to know GLP-1 receptor agonists
The latest Pearls from I.M. Peers offers advice on prescribing glucagon-like peptide-1 (GLP-1) receptor agonists for patients with diabetes.
https://diabetes.acponline.org/archives/2023/03/10/8.htm
10 Mar 2023
Nocturnal hypoglycemia underdiagnosed in older patients on insulin for type 2 diabetes
An industry-funded study of patients age 75 years and older who were taking insulin for type 2 diabetes found that almost two-thirds (65.2%) experienced nocturnal hypoglycemia during a 28-day study period.
https://diabetes.acponline.org/archives/2023/04/14/6.htm
14 Apr 2023
Large review compares benefits, harms of drugs to treat type 2 diabetes
High-certainty evidence indicated that sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists reduce all-cause death, while finerenone probably also reduced mortality based on moderate-certainty evidence.
https://diabetes.acponline.org/archives/2023/05/12/6.htm
12 May 2023
Nonsugar sweeteners should not be used for weight loss, WHO guideline states
The World Health Organization (WHO) cited a lack of evidence suggesting that short-term use of nonsugar sweeteners affected body weight or other measures of adiposity, as well as possible long-term undesirable effects on noncommunicable diseases and death.
https://diabetes.acponline.org/archives/2023/06/09/7.htm
9 Jun 2023